Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORUS-COPE: Modulation of Immunosuppressive Regimen in SOT Recipients With CMV Infection
NCT07570433Phase 4Not yet recruiting
- Sponsor
- Oriol Health Care
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 4 trial of everolimus, mycophenolic acid in cytomegalovirus infection (CMV), sponsored by Oriol Health Care. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
everolimusmycophenolic acid
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07570433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570433.